



## New Frontiers in Treatment of Pancreatic Cancer

Guest Editors:

**Dr. Olav F. Dajani**

Department of Oncology, Oslo  
University Hospital, Oslo, Norway

**Dr. Knut Jørgen Labori**

Department of HBP Surgery, Oslo  
University Hospital, Oslo, Norway

**Dr. Arne Westgaard**

Department of Oncology, Oslo  
University Hospital, 0424 Oslo,  
Norway

Deadline for manuscript  
submissions:

**closed (15 November 2024)**

### Message from the Guest Editors

Pancreatic cancer remains a challenging clinical problem. It is foreseen that the disease will become the second cause of cancer deaths in the western world. To avoid this epidemic, progress will be needed through multiple approaches. In this Special Edition, we therefore welcome original papers and reviews in the following fields of pancreatic cancer research: improved prevention and early diagnostic strategies, molecular tumor stratification for personalized and molecularly targeted antitumor treatment, and the development of rational and tolerable multimodal therapies in the neoadjuvant, adjuvant, and palliative setting, also including radiotherapy.

In addition to tumor-directed treatment, there is a great need to improve quality of life in patients with pancreatic cancer through better symptom control, such as pain management, treatment of cachexia, and psychosocial support, and we also encourage the submission of papers focusing on these.

Dr. Olav F. Dajani

Dr. Knut Jørgen Labori

Dr. Arne Westgaard

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

## Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, and **other databases**.

**Journal Rank:** JCR - Q2 (Oncology)

## Contact Us

Current Oncology Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/currenconcol](http://mdpi.com/journal/currenconcol)  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)  
[X@CurrentOncology](https://twitter.com/CurrentOncology)